CP-169 Effectiveness of biosimilar filgrastim vs original granulocyte-colony stimulating factor (G-CSF) in febrile neutropenia prevention in breast cancer patients receiving docetaxel/doxorubicin/cyclophosphamide (TAC)

I Puértolas Tena; MA Alcácera López; M Merchante Andreu; E Fernández Alonso; M Gimeno Gracia; S Gamarra Calvo; MP Pardo Jario

doi:10.1136/ejhpharm-2016-000875.169

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via EAHP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via EAHP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Alerts

Clinical pharmacy

CP-169 Effectiveness of biosimilar filgrastim vs original granulocyte-colony stimulating factor (G-CSF) in febrile neutropenia prevention in breast cancer patients receiving docetaxel/doxorubicin/cyclophosphamide (TAC)

Log in using your username and password

Main menu

Log in using your username and password

You are here

Read the full text or download the PDF:

Log in using your username and password